Publication Name	World Journal of Diabetes
Manuscript ID	92506
Country	Australia

Received	2024-01-28 06:50
Peer-Review Started	2024-01-28 06:50
To Make the First Decision
Return for Revision	2024-02-08 08:08
Revised	2024-02-14 04:41
Second Decision	2024-02-23 02:40
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-02-23 05:12
Articles in Press	2024-02-23 05:12
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-03-07 03:15
Publish the Manuscript Online	2024-03-15 09:49

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Editorial
Article Title	Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards
Manuscript Source	Invited Manuscript
All Author List	Michael Horowitz, Lu Cai and Md Shahidul Islam
Funding Agency and Grant Number
Corresponding Author	Michael Horowitz, DSc, FRACP, MBBS, PhD, Director, Professor, Department of Medicine, University of Adelaide, Level 5, AHMS Corner North Tce and George St, Adelaide 5005, Australia. michael.horowitz@adelaide.edu.au
Key Words	Glucagon-like-peptide-1; Glucose-dependent insulinotropic peptide; Gastric emptying; Type 2 diabetes
Core Tip	In people who are prescribed a glucagon-like-peptide-1 receptor agonist (GLP-1RA) for management of type 2 diabetes or obesity you should always ask about gastrointestinal symptoms both before and after initiating therapy. Gastrointestinal adverse effects of GLP-1RAs are common, but may not be volunteered.
Publish Date	2024-03-15 09:49
Citation	Horowitz M, Cai L, Islam MS. Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards. World J Diabetes 2024; 15(3): 326-330
URL	https://www.wjgnet.com/1948-9358/full/v15/i3/326.htm
DOI	https://dx.doi.org/10.4239/wjd.v15.i3.326

Full Article (PDF)	WJD-15-326-with-cover.pdf
Full Article (Word)	WJD-15-326.docx
Manuscript File	92506_Auto_Edited-YJP.docx
Answering Reviewers	92506-Answering reviewers.pdf
Audio Core Tip	92506-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	92506-Conflict-of-interest statement.pdf
Copyright License Agreement	92506-Copyright license agreement.pdf
Peer-review Report	92506-Peer-review(s).pdf
Scientific Misconduct Check	92506-Bing-Fan JR-2.png
Scientific Editor Work List	92506-Scientific editor work list.pdf